The Influence of Race and Sex on the Side Effect Profile of Methotrexate in the Treatment of Uveitis

References

• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98 e1.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139.
   PubMed Web of Science ®Google Scholar
• Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131–139.
   PubMed Web of Science ®Google Scholar
• Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm. 2001;9:35–40.
   PubMed Web of Science ®Google Scholar
• Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419–1423.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–1870.
   PubMed Web of Science ®Google Scholar
• Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50:1370–1382.
   PubMed Web of Science ®Google Scholar
• Puchta J, Hattenbach LO, Baatz H. Intraocular levels of methotrexate after oral low-dose treatment in chronic uveitis. Ophthalmologica. 2005;219:54–55.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):423–426.
   PubMed Web of Science ®Google Scholar
• Okada AA. Immunomodulatory Therapy for Ocular Inflammatory Disease: a Basic Manual and Review of the Literature. Ocul Immunol Inflamm. 2009;13:335–351.
   Web of Science ®Google Scholar
• Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008;35(4):572–579.
   PubMed Web of Science ®Google Scholar
• Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–271.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1997;40(7):1308–1315.
   PubMed Web of Science ®Google Scholar
• Gilani ST, Khan DA, Khan FA, Ahmed M. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012;22:101–104.
   PubMed Web of Science ®Google Scholar
• Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44:61–66.
   PubMed Web of Science ®Google Scholar
• Attar SM. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based study. Saudi Med J. 2010;31:909–915.
   PubMed Web of Science ®Google Scholar
• Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS. Adverse drug reactions caused by methotrexate in Saudi population. Saudi Pharm J. 2012;20:301–305.
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis. 2010;69(6):1044–1048.
   PubMed Web of Science ®Google Scholar
• Dubey L, Chatterjee S, Ghosh A. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: an observational study. Indian J Pharmacol. 2016;48:591–594.
   PubMed Web of Science ®Google Scholar
• Van Scott EJ, Reinertson RP, Steinmuller R. The growing hair roots of the human scalp and morphologic changes therein following amethopterin therapy. J Invest Dermatol. 1957;29:197–204.
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig. 2010;30:101–108.
   PubMed Web of Science ®Google Scholar
• Song GG, Bae SC, Lee YH. Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2014;33:1715–1724.
   PubMed Web of Science ®Google Scholar
• Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002;12(3):183–190.
   PubMedGoogle Scholar
• Hughes LB, Beasley TM, Patel H, et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2006;65(9):1213–1218.
   PubMed Web of Science ®Google Scholar
• van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 2001;44(11):2525.
   PubMed Web of Science ®Google Scholar